Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), LifeMD (LFMD) and Novo Nordisk (NVO)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zai Lab (ZLAB – Research Report), LifeMD (LFMD – Research Report) and Novo Nordisk (NVO – Research Report).
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Zai Lab (ZLAB)
Bank of America Securities analyst David Li maintained a Hold rating on Zai Lab today and set a price target of $38.20. The company's shares closed last Tuesday at $37.22, close to its 52-week high of $39.77.
Li has an average return of 17.5% when recommending Zai Lab. ;'>
According to TipRanks.com, Li is ranked #6632 out of 9628 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zai Lab with a $53.04 average price target.
LifeMD (LFMD)
In a report released today, David Larsen from BTIG maintained a Buy rating on LifeMD, with a price target of $18.00. The company's shares closed last Tuesday at $13.58.
According to TipRanks.com, Larsen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.1% and a 29.7% success rate. Larsen covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, P3 Health Partners, and Oncology Institute. ;'>
LifeMD has an analyst consensus of Strong Buy, with a price target consensus of $12.00.
Novo Nordisk (NVO)
TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk today and set a price target of $105.00. The company's shares closed last Tuesday at $74.34, close to its 52-week low of $69.18.
According to TipRanks.com, Nedelcovych is ranked 0 out of 5 stars with an average return of -12.6% and a 33.3% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Takeda Pharmaceutical Company, Bausch Health Companies, and Molecular Partners AG. ;'>
Novo Nordisk has an analyst consensus of Hold, with a price target consensus of $92.71.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
Here's Why Wall Street Is Bullish on AI Stock Vertiv Holdings (VRT)
Vertiv Holdings (VRT) stock has recovered strongly from the lows seen in April and has risen more than 11% over the past month, as concerns about a slowdown in AI (artificial intelligence) spending have eased. VRT stock has rallied more than 30% in the past year. The data center infrastructure company is gaining from the strong demand for its energy-efficient cooling and power solutions that are required to support the ongoing AI boom. Confident Investing Starts Here: Vertiv: Riding the AI Wave Vertiv impressed investors with solid Q1 earnings beat. The company's Q1 2025 revenue grew 24%, while adjusted EPS (earnings per share) increased by about 49%. The AI infrastructure company also raised its full-year guidance, reflecting confidence in navigating macro challenges and mitigating the impact of tariffs announced by the Trump administration. 'Our partnership with Nvidia continues to place us at the heart of industrial-scale AI factory deployments,' said VRT CEO Giordano Albertazzi. Recently, Vertiv further strengthened its collaboration with chip giant Nvidia (NVDA) and announced an energy-efficient 142kW cooling and power reference architecture for the latter's GB300 NVL72 platform. Overall, VRT is confident about its growth ahead, with a 10% rise in Q1 2025 backlog to $7.9 billion compared to the end of 2024. Analysts Raise Price Target for VRT Stock on AI Demand Recently, Bank of America analyst Andrew Obin reiterated a Buy rating on Vertiv stock and increased the price target to $140 (17.8% upside potential) from $135. The 5-star analyst emphasized that the rapid advancement of AI is transforming the data center infrastructure landscape, driving robust demand for power, cooling, and advanced hardware. BofA expects data center spending to grow at a 13% CAGR (compound annual growth rate) from 2024 to 2028, reaching $532 billion. In fact, he expects infrastructure-related spending to climb at an even faster 16% CAGR. Notably, Obin believes that Vertiv, Eaton (ETN), and Johnson Controls (JCI) are well-positioned to leverage the shift toward high-density racks and advanced cooling solutions like direct-to-chip liquid cooling. He also named GE Vernova (GEV) as a top pick in the power generation space, citing its potential to meet rising demand. With only 5% of existing data centers equipped to handle AI workloads, Obin expects a massive upgrade cycle ahead. Also, with AI-driven demand showing no signs of slowing, Obin is upbeat about these stocks. Meanwhile, Citi analyst Andrew Kaplowitz increased the price target for VRT stock to $130 (9.4% upside potential) from $98 and reaffirmed a Buy rating. Following a meeting with the management, the 5-star analyst stated that he is confident that Vertiv remains well-positioned for huge industrial market outgrowth, thanks to durable AI/data center-related growth (Citi forecasts overall global data center IT load growth at 14% CAGR through 2030) and its focus on innovation. Kaplowitz also highlighted VRT's efforts to mitigate tariff headwinds over time. Citing the possibility for margin expansion, strong underlying fundamentals, and increased confidence in improving performance, Kaplowitz increased the EV/EBITDA target multiple for VRT stock to 21x from 16x. Is VRT a Good Stock to Buy? Overall, Vertiv Holdings stock scores a Strong Buy consensus rating based on 12 Buys and two Holds. The average VRT stock price target of $116.93 indicates a possible downside of 1.6% from current levels, following the strong rally over the past year.
CTV News
28 minutes ago
- CTV News
Does face yoga actually work? Experts weigh in on its slimming, anti-aging effects
Face yoga involves a series of poses and stretches, as well as massage of the face. Oscar Gutierrez Zozulia/iStockphoto/Getty Images via CNN Newsource Puckering, puffing, scrunching and stretching your face may look silly, but in some spaces, it's the serious business of face yoga. The trendy facial workout involves a series of exaggerated poses and repetitive movements meant to target the muscles in the face, trading full-bodied yoga moves such as 'downward dog' for the lip-pouting 'duckface' and other expressions. Popular for being both cost-effective and product-free, face yoga testimonies can be found all over social media, with some influencers and self-proclaimed gurus promising a 'natural facelift' effect capable of toning, slimming and reducing fine lines on the face. But how much are these promised benefits a stretch of the truth? And how much is backed by science? Here's what a yoga instructor, a dermatologist and the author of one of the few face yoga studies out there have to say. The science behind face yoga The face is made up of layers of skin, fat and muscle sitting on top of the skull. Underneath the top layer of skin, or dermis, there is a layer of subcutaneous fat pads, which sit on top of the muscles, explained Dr. Anetta Reszko, a New York-based dermatologist and clinical assistant professor of dermatology at Weill Cornell Medical College. These muscles help us smile, frown, chew and make other facial expressions. 'The fat and the muscles work together to give the face volume,' Reszko said. 'But over time, as we age, or if we don't use those muscles because of Botox, they can atrophy (and) become smaller.' This atrophy can cause the fat pads on top of the muscles to fall, giving the face a more sagging or hollow appearance, Reszko said. 'The idea behind facial yoga is you're working below that level, growing the muscle layer below the fat,' said Dr. Murad Alam, the vice chair of the department of dermatology and professor at Northwestern University's Feinberg School of Medicine in Chicago. 'As you grow the muscle, that would restore some shape to the face.' Alam, who is also a practicing dermatologist, conducted one of the few known studies to test this face yoga hypothesis in 2018 on a small cohort of middle-aged adults. After 20 weeks of daily, 30-minute exercises, a panel of dermatologists observed improved facial fullness among the 16 participants who completed the program, the study reported. 'The place where we noticed the biggest change was the cheeks,' Alam said. 'Which makes sense, because the cheek muscles are among the biggest facial muscles, so if you exercise them, the growth of them is going to be the most noticeable.' Due to the limited sample size and lack of direct measurements, further clinical trials would be needed to affirm this volumizing effect, Alam noted. Generally, medical research without a drug or device is difficult to fund, he said. 'Is this a replacement for cosmetic procedures? Not really, because the amount of improvement was not as significant and (other cosmetic) aspects of aging weren't studied,' Alam said. 'But it's potentially useful to people who absolutely do not want any cosmetic procedures because they're concerned about the safety or the cost or the inconvenience.' What else could face yoga do? In Reszko's dermatology practice, she recommends face yoga exercises for increasing blood and lymphatic fluid circulation in the face. Our faces have hundreds of lymph nodes that use fluid to drain waste and fight infection, Reszko said. During sleep, lymphatic fluid can accumulate in the face from lying down, causing a 'puffy' appearance immediately upon waking. Moving, stretching and massaging the face for 10 to 15 minutes every day could help reduce puffiness, Reszko said, referencing other techniques such the traditional Chinese gua sha stones that are meant to serve a similar purpose. This drainage can be especially helpful for patients who recently underwent cosmetic surgery or those with chronic allergies, she said. Increasing blood flow to the face may also make the skin appear more flushed and hydrated as well, Reszko said, but this effect is usually temporary. If you tend to hold tension in your neck, shoulders, jaw, forehead or anywhere else on the face, face yoga also could be helpful to relax the muscles, said Annelise Hagen, a yoga instructor and self-proclaimed pioneer of the technique who authored the book 'The Yoga Face.' 'Tension is a huge enemy for a lot of us. We are making these faces without realizing it all the time.' Hagen said. 'A lot of the work I do is just trying to teach people how to notice and be more mindful, relax and take a breath.' For Hagen, face yoga is more than just a workout or a cosmetic bio-hack — it's a way to be more in tune with your face. In her classes, she may encourage people to lift the corners of their mouth for a neutral, 'smiling Buddha face.' Or for the neck and jaw, she'll do the 'lion's breath,' opening her mouth wide, sticking out her tongue, rolling back her eyes and exhaling. 'When you're approaching the face from a yogic perspective, it's about being mindful of what we do with the face and acknowledging that it's kind of a manifestation of something inside,' Hagen said. 'Some people may approach it differently, but anything that can make you feel more serene, calm and better about the face that you're in, I think is legitimate.' Can face yoga be harmful? Generally, face yoga exercises are harmless, Alam said. To cause wrinkling, frown lines, bruising or other trauma to the face, a person would have to apply painful force. On the other hand, if someone is serious about taking up a daily face yoga routine, Reszko suggests avoiding movements that rub or stretch the delicate under-eye area. The skin around the eyes tends to be thinner and more sensitive than the rest of the face. For more dramatic interventions like firming wrinkles or treating acne, she recommends seeking the advice of a board-certified dermatologist.
Globe and Mail
an hour ago
- Globe and Mail
NVDA, TSMC, AVGO: Chip Stocks Fall on Reports U.S. May Further Restrict Exports to China
Leading semiconductor stocks such as Nvidia (NVDA), Broadcom (AVGO), and Taiwan Semiconductor Manufacturing Co. (TSM) are down on June 20 as reports surface that the U.S. government may further restrict the export of microchip and semiconductor technology to China. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Specifically, the U.S. Commerce Department is considering terminating waivers that allow some chipmakers to send American technology to factories in China, including Taiwan Semiconductor that is based in the Chinese territory of Taiwan and manufactures about two-thirds of the world's microchips. Other chip and semiconductor stocks that are down on news of the potential U.S. government curbs include Qualcomm (QCOM) and Marvell Technology (MRVL). The latest move by the U.S. government comes as America and China hold a loose agreement on tariffs and an uneasy truce in their ongoing trade battle. Controls around microchips and semiconductors reportedly remain a sticking point. Digital Oil Microchips and semiconductors are often referred to as the oil of the 21st Century or digital oil. The U.S. has issued several chip export changes this year under the administration of U.S. President Donald Trump. China has called the U.S. rule changes 'discriminatory' and retaliated by restricting some critical metals and rare earth minerals. For U.S. chipmakers such as Nvidia and Broadcom, these would be the latest government curbs that could impact their global sales, limiting their ability to sell advanced artificial intelligence (AI) chips into China due to national security concerns. During its most recent earnings report, Nvidia said current export restrictions on its China-bound microchips cost the company about $8 billion in lost sales. Is NVDA Stock a Buy? The stock of Nvidia has a consensus Strong Buy rating among 40 Wall Street analysts. That rating is based on 35 Buy, four Hold, and one Sell recommendations assigned in the last three months. The average NVDA price target of $173.19 implies 19.05% upside from current levels.
